Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06100510
Other study ID # HOACNYPFA100.001
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date November 2023
Est. completion date January 2024

Study information

Verified date October 2023
Source Hematology Oncology Associates of Central New York
Contact Eric A Walradth, MA,MLS(ASCP)
Phone (315) 472-7504
Email ewalradth@hoacny.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research is to evaluate instrument functionality and develop a reference range of normal data by healthy volunteers.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date January 2024
Est. primary completion date January 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years or older - Able to consent to study Exclusion Criteria from entire study - Primary hemostasis diagnosis - Von Willebrand Disease - Bernard-Soulier syndrome - Glanzmann thrombasthenia - Idiopathic thrombocytopenic purpura - Drug-induced thrombocytopenia - Heparin-induced thrombocytopenia - Thrombotic thrombocytopenic purpura - Hemolytic uremic syndrome - Participant is on anticoagulant therapy - Specifically thienopyrdines [Ticlopidine, Clopidogrel] and GPIIb/IIIa inhibitors [ReoPro, Aggrastat, Integrilin] - Participant is on medication that contains ASA or aspirin (see list below in Study Procedure) - Participant is on nonsteroidal anti-inflammatory agents that are known to induce temporary platelet dysfunction (see list below in Study Procedure) - Participant is on non-prescription medications containing aspirin (see list below in Study Procedure) - PFA-100 result falls outside of reference interval listed in the package insert (suggested criteria in the PFA-100 Evaluation Protocol as described in the PFA-100 System: Getting Started Guide) - If hematocrit is less than 35% - If platelets are less than 150 x10^3/uL Exclusion Criteria from Cohort B but not Cohort A - Potential for adverse reactions between current medication and aspirin as dictated by staff pharmacist - Allergy to ASA or aspirin - Previous allergic reaction to ASA or aspirin - Participant is pregnant - Asthma, or history of, with nasal polyps and rhinitis - Stomach ulcers or bleeding - Severe kidney disease - Severe liver disease - Hemophilia - Pregnant or breast feeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Aspirin 325mg
Cohort B will receive one (1) 325 mg aspirin 24 hours prior to their second blood draw.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hematology Oncology Associates of Central New York

Outcome

Type Measure Description Time frame Safety issue
Primary Instrument Evaluation Protocol-PFA100 Instrumentation [platelet function as measured by aperture closure time monitored in seconds for collagen/epinephrine (COL/EPI) cartridges and collagen/ADP (COL/ADP) cartridges] This portion of the study is to ensure that the functionality of the instrumentation is working properly.
For each participant, their pre-aspirin dose closure times will be compared to their post-aspirin dose closure times.
The typical pattern seen in subjects with normal platelet function (pre-aspirin testing) is closure time (CT) results within the reference range for both the COL/EPI and COL/ADP cartridges (normal).
In general, the pattern seen after aspirin ingestion is a CT result outside the reference range (abnormal) with COL/EPI and within the reference range for COL/ADP (normal).
3 months
Primary Reference Interval Protocol-PFA100 Instrumentation [platelet function as measured by aperture closure time monitored in seconds for collagen/epinephrine (COL/EPI) cartridges and collagen/ADP (COL/ADP) cartridges] For each participant in the non-intervention/placebo arm, platelet function as measured by aperture closure time monitored in seconds for collagen/epinephrine (COL/EPI) cartridges and collagen/ADP (COL/ADP) cartridges will be captured.
Following guidelines as stated per CLSI document EP28-A3c, a reference interval will be developed from this captured data.
3 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04549012 - Determination of Blood Loss After CS Early Phase 1
Active, not recruiting NCT06114758 - Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
Completed NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Recruiting NCT04573049 - The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement Phase 4
Not yet recruiting NCT04562493 - Comparative Effect of Transforaminal Injection of Magnesium Sulphate Versus Ozone Therapy on Oxidative Stress Biomarkers in Lumbar Disc Related Radicular Pain N/A
Completed NCT04762147 - Comparison of Perioperative Analgesia Between Intravenous Paracetamol and Fentanyl for Rigid Hysteroscopy Phase 3
Not yet recruiting NCT05510986 - The Effect of Oxycodone Hydrochloride on CRBD After TURBT Under General Anesthesia N/A
Completed NCT06432309 - Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease N/A
Recruiting NCT05968885 - Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity Phase 4
Recruiting NCT05092074 - Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
Recruiting NCT05595044 - Effect of Vitamin D Therapy in Autism Spectrum Disorder Phase 1
Completed NCT05060913 - Emla Cream Versus Benzocaine on Analgesia Early Phase 1
Not yet recruiting NCT05293119 - Role of Tofacitinib in Vitiligo Patients Early Phase 1
Not yet recruiting NCT06414018 - Effect of Equivalent Dose Sufentanil and Afentanil in Bronchoscopic Treatment N/A
Recruiting NCT05786859 - The Efficacy and Safety of Rifaximin Treatment Early Phase 1
Not yet recruiting NCT06290219 - The Effect of Platelet-rich Plasma Nasal Injection in the Treatment of Traumatic Olfactory Dysfunction Phase 3
Completed NCT05277480 - Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) Phase 2
Recruiting NCT05482451 - Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer Early Phase 1
Not yet recruiting NCT04892212 - Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis Phase 2/Phase 3
Not yet recruiting NCT05918146 - Dextrose Therapy on Physical Therapy in Subdeltoid Bursitis Phase 4